(NYSE: MRK) Merck & Co's forecast annual revenue growth rate of 4.8% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.24%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.02%.
Merck & Co's revenue in 2026 is $65,768,000,000.On average, 30 Wall Street analysts forecast MRK's revenue for 2026 to be $166,436,527,678,020, with the lowest MRK revenue forecast at $159,688,967,376,240, and the highest MRK revenue forecast at $175,036,456,291,050. On average, 29 Wall Street analysts forecast MRK's revenue for 2027 to be $175,503,253,105,485, with the lowest MRK revenue forecast at $164,813,853,037,365, and the highest MRK revenue forecast at $187,383,108,541,635.
In 2028, MRK is forecast to generate $187,543,647,128,610 in revenue, with the lowest revenue forecast at $173,989,250,739,090 and the highest revenue forecast at $205,926,550,249,455.